A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing

• DOI: 10.1016/j.jtho.2016.05.032
• Publication Date: 2016-06-18T22:12:12Z
• Authors: Klazien Matter-Wa...; Matthias Schwenkg...; Stefan Aebi; Konstantin Dedes; Joachim Diebold; Mario Pietrini; Dirk Klingbiel; Roger von Moos; Oliver Gautschi
• Keywords: Male; 0301 basic medicine; Lung Neoplasms; Cost-Benefit Analysis; Antibodies, Monoclonal; 610 Medicine & health; Antineoplastic Agents; 10060 Epidemiology, Biostatistics and Prevention Institute (EBPI); Docetaxel; 10174 Clinic for Gynecology; B7-H1 Antigen; 3. Good health; 03 medical and health sciences; Nivolumab; 2740 Pulmonary and Respiratory Medicine; Carcinoma, Non-Small-Cell Lung; Humans; 2730 Oncology; Female; Taxoids; Quality-Adjusted Life Years

Nivolumab (NIV) was recently approved in several countries for patients with pretreated advanced NSCLC. NIV is not cost-effective compared with docetaxel (DOC) for the treatment of squamous NSCLC. However, its cost-effectiveness for nonsquamous NSCLC and the consequences of programmed death ligand 1 (PD-L1) testing are unknown.This literature-based health economic study used CheckMate-057 trial data to model the incremental cost-effectiveness ratio (ICER) of NIV versus DOC in the Swiss health care setting. The effect of PD-L1 positivity for patient selection was assessed.In the base case model, NIV (mean cost CHF66,208; mean effect 0.69 quality-adjusted life-years [QALYs]) compared with DOC (mean cost CHF37,618; mean effect 0.53 QALYs) resulted in an ICER of CHF177,478/QALY gained. Treating only patients with PD-L1-positive tumors (threshold ≥10%) with NIV compared with treating all patients with DOC produced a base case ICER of CHF124,891/QALY gained. Reduced drug price, dose, or treatment duration decreased the ICER partly below a willingness-to-pay threshold of CHF100,000/QALY. Health state utilities strongly influenced cost-effectiveness.Compared with DOC, NIV is not cost-effective for the treatment of nonsquamous NSCLC at current prices in the Swiss health care setting. Price reduction or PD-L1 testing and selection of patients for NIV on the basis of test positivity improves cost-effectiveness compared with DOC.